Singapore
LambdaGen Pte. Ltd. is pioneering the development of personalized stem-cell based therapeutics for rare genetic diseases and cancer. With its proprietary non-viral genome insertion system based on λ-integrase, the company aims to revolutionize therapeutic solutions. Founded in 2019, LambdaGen's platform allows the insertion of large DNA fragments at specific sites in the human genome, empowering the R&D efforts for tackling genetic diseases and cancer immunotherapy.
Specializing in the biotechnology, healthcare, and wellness industries, LambdaGen's innovative approach holds substantial promise for addressing unmet medical needs. As a gateway to safer therapeutics, the company's vision aligns with the growing demand for personalized and targeted treatment options in the healthcare landscape. However, specific details regarding the company's headquarters, last investment, and investors are not available at the moment.
